Adaptimmune Therapeutics (ADAP) Tops Q4 EPS by 21c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q4 EPS of ($0.03), $0.21 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $11.03 million versus the consensus estimate of $3.83 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• Bernstein SocGen Group Reiterates Outperform Rating on Centene (CNC), discusses CFO change